Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

The need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant responses in these patients. METHODS: This is a multicen...

Descripción completa

Detalles Bibliográficos
Autores principales: Giné, Eva, de la Cruz, Fátima, Jiménez Ubieto, Ana, López Jimenez, Javier, Martín García-Sancho, Alejandro, Terol, M. José, González Barca, Eva, Casanova, María, de la Fuente, Adolfo, Marín-Niebla, Ana, Muntañola, Ana, González-López, Tomás José, Aymerich, Marta, Setoain, Xavier, Cortés-Romera, Montserrat, Rotger, Amanda, Rodríguez, Sonia, Medina Herrera, Alejandro, García Sanz, Ramón, Nadeu, Ferran, Beà, Silvia, Campo, Elías, López-Guillermo, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987223/
https://www.ncbi.nlm.nih.gov/pubmed/35030036
http://dx.doi.org/10.1200/JCO.21.02321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987223/
https://www.ncbi.nlm.nih.gov/pubmed/35030036
http://dx.doi.org/10.1200/JCO.21.02321

Ejemplares similares